Mesoblast (MEOBF) Equity Average (2018 - 2022)

Mesoblast (MEOBF) has disclosed Equity Average for 5 consecutive years, with $539.2 million as the latest value for Q2 2022.

  • Quarterly Equity Average fell 4.62% to $539.2 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $539.2 million through Jun 2022, down 4.62% year-over-year, with the annual reading at $539.2 million for FY2022, 4.62% down from the prior year.
  • Equity Average hit $539.2 million in Q2 2022 for Mesoblast, down from $565.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $565.4 million in Q2 2021 to a low of $513.5 million in Q2 2019.
  • Historically, Equity Average has averaged $532.9 million across 5 years, with a median of $531.4 million in 2018.
  • Biggest five-year swings in Equity Average: grew 9.74% in 2021 and later decreased 4.62% in 2022.
  • Year by year, Equity Average stood at $531.4 million in 2018, then fell by 3.36% to $513.5 million in 2019, then grew by 0.32% to $515.2 million in 2020, then increased by 9.74% to $565.4 million in 2021, then fell by 4.62% to $539.2 million in 2022.
  • Business Quant data shows Equity Average for MEOBF at $539.2 million in Q2 2022, $565.4 million in Q2 2021, and $515.2 million in Q2 2020.